Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

Carboplatin 90pembrolizumab 73Pemetrexed 66Cisplatin 56atezolizumab 31Paclitaxel 31Docetaxel 30durvalumab 28Specimen Handling 26Nivolumab 26Magnetic Resonance Spectroscopy 21osimertinib 20Gemcitabine 19130-nm albumin-bound paclitaxel 18Etoposide 17Cetuximab 16Radiotherapy 14Platinum 131,2-diaminocyclohexaneplatinum II citrate 11amivantamab 10Taxes 10Immunoglobulin G 10Radiation 9PM 01183 9Ipilimumab 9Disulfides 9Bevacizumab 9Topotecan 8lazertinib 7fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ebselen × Thoracic × 30 days × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡